

PTC2 (PRKAR1A-RET), Active

Recombinant human fusion protein expressed in Sf9 cells

Catalog # **R02-19CG**

Lot # A1353-4

Product Description

Recombinant human RET/PTC2, the fusion protein [PRKAR1A (1-236)-RET (713-end)], was expressed by baculovirus in Sf9 insect cells using an N-terminal GST tag. The PRKAR1A gene accession number is [NM_002734](#) and RET's one is [NM_020630](#).

Gene Aliases

PRKAR1A: CAR; CNC; CNC1; PKR1; PPNAD1; PRKAR1; TSE1
RET: CDHF12, RET51, PTC, RET-ELE1; RET/PTC2

Formulation

Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol.

Storage and Stability

Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.


Scientific Background

RET/PTC2 is fused of the tyrosine-kinase domain of proto-RET with the regulatory subunit R/A of c-AMP-dependent protein kinase A, by transforming a chromosomal translocation at t(10;17)(q11.2;q23) (1). The RET/PTC oncoproteins display constitutive TK activity and tyrosine phosphorylation. The RET/PTC2 Tyr-539 is an essential docking site for activating the SH2-containing transducer phospholipase PLCgamma (2). The RET/PTC2 activation may play crucial roles in papillary thyroid tumorigenesis and neoplastic oncogene.

References


1. Gabriella S. et al: A t(10; 17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. *Genes, Chromosomes and Cancer*. 9:244-250 (1994).
2. M G Borrello, et al: The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. *Mol Cell Biol*. May 1996; 16(5): 2151-2163.

Specific Activity



The specific activity of PTC2 (PRKAR1A-RET) was determined to be **280 nmol /min/mg** as per activity assay protocol.

Purity



The purity of PTC2 (PRKAR1A-RET) was determined to be **>85%** by densitometry, approx. MW **105 kDa**.

PTC2 (PRKAR1A-RET), Active

Recombinant human fusion protein expressed in Sf9 cells

Catalog #	R02-19CG
Specific Activity	280 nmol/min/mg
Lot #	A1353-4
Purity	>85%
Concentration	0.1 µg/µl
Stability	1yr at -70°C from date of shipment
Storage & Shipping	Store product at -70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles. Product shipped on dry ice.

To place your order, please contact us by phone 1-(604)-232-4600, fax 1-604-232-4601 or by email: orders@signalchem.com
www.signalchem.com

FOR IN VITRO RESEARCH PURPOSES ONLY. NOT INTENDED FOR USE IN HUMAN OR ANIMALS.

Activity Assay Protocol

Reaction Components

Active Kinase (Catalog #: R02-19CG)

Active PTC2 (PRKAR1A-RET) (0.1µg/µl) diluted with Kinase Dilution Buffer III (Catalog #: K23-09) and assayed as outlined in sample activity plot. (Note: these are suggested working dilutions and it is recommended that the researcher perform a serial dilution of Active PTC2 (PRKAR1A-RET) for optimal results).

Kinase Dilution Buffer III (Catalog #: K23-09)

Kinase Assay Buffer I (Catalog #: K01-09) diluted at a 1:4 ratio (5X dilution) with 50ng/µl BSA solution.

Kinase Assay Buffer I (Catalog #: K01-09)

Buffer components: 25mM MOPS, pH 7.2, 12.5mM β-glycerol-phosphate, 25mM MgCl₂, 5mM EGTA, 2mM EDTA. Add 0.25mM DTT to Kinase Assay Buffer prior to use.

[³³P]-ATP Assay Cocktail

Prepare 250µM [³³P]-ATP Assay Cocktail in a designated radioactive working area by adding the following components: 150µl of 10mM ATP Stock Solution (Catalog #: A50-09), 100µl [³³P]-ATP (1mCi/100µl), 5.75ml of Kinase Assay Buffer I (Catalog #: K01-09). Store 1ml aliquots at -20°C.

10mM ATP Stock Solution (Catalog #: A50-09)

Prepare ATP stock solution by dissolving 55mg of ATP in 10ml of Kinase Assay Buffer I (Catalog #: K01-09). Store 200µl aliquots at -20°C.

Substrate (Catalog #: I15-58)

IGF1Rtide synthetic peptide substrate (KKKSPGEYVNIIEFG) diluted in distilled H₂O to a final concentration of 1mg/ml.

Assay Protocol

- Step 1.** Thaw [³³P]-ATP Assay Cocktail in shielded container in a designated radioactive working area.
- Step 2.** Thaw the Active PTC2 (PRKAR1A-RET), Kinase Assay Buffer, Substrate and Kinase Dilution Buffer on ice.
- Step 3.** In a pre-cooled microfuge tube, add the following reaction components bringing the initial reaction volume up to 20µl:
 - Component 1.** 10µl of diluted Active PTC2 (PRKAR1A-RET) (Catalog #R02-19CG)
 - Component 2.** 5µl of 1mg/ml stock solution of substrate (Catalog #I15-58)
 - Component 3.** 5µl distilled H₂O (4°C)
- Step 4.** Set up the blank control as outlined in step 3, excluding the addition of the substrate. Replace the substrate with an equal volume of distilled H₂O.
- Step 5.** Initiate the reaction by the addition of 5 µl [³³P]-ATP Assay Cocktail bringing the final volume up to 25µl and incubate the mixture in a water bath at 30°C for 15 minutes.
- Step 6.** After the 15 minute incubation period, terminate the reaction by spotting 20 µl of the reaction mixture onto individual pre-cut strips of phosphocellulose P81 paper.
- Step 7.** Air dry the pre-cut P81 strip and sequentially wash in a 1% phosphoric acid solution (dilute 10ml of phosphoric acid and make a 1L solution with distilled H₂O) with constant gentle stirring. It is recommended that the strips be washed a total of 3 intervals for approximately 10 minutes each.
- Step 8.** Count the radioactivity on the P81 paper in the presence of scintillation fluid in a scintillation counter.
- Step 9.** Determine the corrected cpm by removing the blank control value (see Step 4) for each sample and calculate the kinase specific activity as outlined below.

Calculation of [³³P]-ATP Specific Activity (SA) (cpm/pmol)

Specific activity (SA) = cpm for 5 µl [³³P]-ATP / pmoles of ATP (in 5 µl of a 250 µM ATP stock solution, i.e., 1250 pmoles)

Kinase Specific Activity (SA) (pmol/min/µg or nmol/min/mg)

Corrected cpm from reaction / [(SA of ³³P-ATP in cpm/pmol)*(Reaction time in min)*(Enzyme amount in µg or mg)]*[(Reaction Volume) / (Spot Volume)]

To place your order, please contact us by phone 1-(604)-232-4600, fax 1-604-232-4601 or by email: orders@signalchem.com
www.signalchem.com

FOR IN VITRO RESEARCH PURPOSES ONLY. NOT INTENDED FOR USE IN HUMAN OR ANIMALS.